Atossa Therapeutics Inc. Common Stock (ATOS)
Stock · NASDAQ · Health Care
$2.93as of 10/16/2026
Price chart
Active signals
ATOS Signal Track Record
How signals performed across all stocks →What ATOS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -11.1% | 30% | September 22, 2026 |
| Bollinger Band BreakoutActive now | 24 | -6.9% | 25% | August 14, 2026 |
| Bollinger Band Breakdown | 20 | -5.4% | 40% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -8.4% | 44% | December 9, 2025 |
| Any 20-session window (baseline) | -4.0% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other thera…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 16
- Website
- atossatherapeutics.com/
Fundamentals
- 1-day range
- $2.51$2.95
- Market cap
- $20.84M
- P/E (trailing)
- —
- P/E (forward)
- -0.88
- EPS (trailing)
- $-4.34
- Dividend yield
- —
- Beta
- 1.39
- Avg. volume
- 68.7K
- Dividend pay date
- April 20, 2018
How Atossa Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2015 annual results
Source: 10-K filed Mar 30, 2016 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Atossa Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ATOSAtossa Therapeutics Inc. Common Stock$2.91▲ 9.81%Market cap $20.84MP/E —$1.7$16.5
- QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$2.47▼ 8.86%Market cap $20.67MP/E —$2.85$23.1
- NEUPNeuphoria Therapeutics Inc. Common Stock$3.3▼ 0.30%Market cap $21.08MP/E —$3.19$17.9
- NXTCNextCure Inc. Common Stock$6.24▼ 9.30%Market cap $20.19MP/E —$1.55$15.74
- CLRBCellectar Biosciences Inc. Common Stock$1.14▼ 4.20%Market cap $20.14MP/E —$1.15$5.07
- ALLRAllarity Therapeutics Inc. Common Stock$0.895▲ 7.44%Market cap $21.65MP/E —$0.769$1.84
- DAREDare Bioscience Inc. Common Stock$0.725▼ 2.03%Market cap $19.92MP/E —$0.69$3.78
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ATOS Atossa Therapeutics Inc. Common Stock | $20.84M | — | $2.91 | ▲ 9.81% | $1.7$16.5 |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $20.67M | — | $2.47 | ▼ 8.86% | $2.85$23.1 |
| NEUP Neuphoria Therapeutics Inc. Common Stock | $21.08M | — | $3.3 | ▼ 0.30% | $3.19$17.9 |
| NXTC NextCure Inc. Common Stock | $20.19M | — | $6.24 | ▼ 9.30% | $1.55$15.74 |
| CLRB Cellectar Biosciences Inc. Common Stock | $20.14M | — | $1.14 | ▼ 4.20% | $1.15$5.07 |
| ALLR Allarity Therapeutics Inc. Common Stock | $21.65M | — | $0.895 | ▲ 7.44% | $0.769$1.84 |
| DARE Dare Bioscience Inc. Common Stock | $19.92M | — | $0.725 | ▼ 2.03% | $0.69$3.78 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Atossa Therapeutics Inks Stapled Contingent Value Rights Agreement With VStock Transfer; Atossa Declares Dividend Of One Stapled CVR For Each Share Of Atossa Common Stockbenzinga · 10/9/2026
- Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher ValueYahoo · 10/9/2026
- Atossa Therapeutics Inks Stapled Contingent Value Rights Agreement With VStock Transfer; Atossa Declares Dividend Of One Stapled CVR For Each Share Of Atossa Common StockBenzinga · 10/9/2026
- Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25Benzinga · 10/1/2026
- Atossa plans shareholder stake in potential PRV proceedsYahoo · 9/30/2026
- Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review VoucherYahoo · 9/29/2026
- Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of AgingYahoo · 9/24/2026
Insider Activity
Insider Actions →- Shu-Chih Chen · May 12, 2026 · Grant10.0K
- H. Lawrence Remmel · May 12, 2026 · Grant10.0K
- Jonathan Finn · May 12, 2026 · Grant10.0K
- Stephen J. Galli · May 12, 2026 · Grant10.0K
- Tessa Cigler · May 12, 2026 · Grant10.0K
- Richard I. Steinhart · May 12, 2026 · Grant10.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.24M
- Total value held
- $6.51M
- Institutional holders
- 29
- Unknown349.1K
- Unknown255.1K
- Unknown133.2K
- Unknown109.0K
- Unknown97.1K
- Unknown92.0K
- Unknown66.7K
- Unknown55.0K
- Unknown39.8K
- Unknown19.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Atossa Announces Stapled CVR Plan and Raises Price Target
Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.
Atossa Announces Stapled CVR Plan and Raises Price Target. Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.